Share-Based Compensation Through the Grant of Stock Acquisition Rights to 5 Directors
First written in FY2019-Q2. 11 of 14 entries say "Advanced", first in FY2021. Latest entry: FY2026.
- FY2026AdvancedAnnual report
「Opening outstanding balance 3,813,000 859 Granted － － Exercised 684,900 465 Forfeited 162,900 784 Expired 397,200 465 Closing outstanding balance 2,568,000 1,031」
During the year, stock acquisition rights covering 684,900 shares were exercised, 162,900 shares were forfeited, and 397,200 shares expired. The closing outstanding balance of the 2024 stock options was 2,568,000 shares. - 2026-06-04AdvancedGeneral Meetings of Shareholders
「Common stock 288,477,042 shares 684,900 shares － 289,161,942 shares」
The number of common shares increased by 684,900 during the consolidated fiscal year through the exercise of stock acquisition rights. - FY2026-H1AdvancedAnnual report
「1 April 2025–30 September 2025 (Note) 312,000 288,789,042 94 25,759 94 6,993 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the six-month consolidated accounting period, 312,000 shares were added through the exercise of stock acquisition rights, increasing share capital and capital surplus by ¥94 million each. - FY2025AdvancedAnnual report
「2024 stock options 2,659,800 26 November 2024 From 1 November 2026 To 31 October 2028」
As 2024 stock options, granted rights covering 2,659,800 shares to directors, executive officers, employees, and officers and employees of subsidiaries. During the year, existing stock options covering 696,900 shares were exercised. - FY2025-H1AdvancedAnnual report
「1 April 2024–30 September 2024 (Note) 385,800 288,165,942 116 25,571 116 6,804 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the six-month consolidated accounting period, 385,800 shares were added through the exercise of stock acquisition rights, increasing share capital and capital surplus by ¥116 million each. - FY2024AdvancedAnnual report
「After vesting (shares) End of previous consolidated fiscal year － Vested 2,324,100 Exercised 421,500 Forfeited 59,100 Outstanding 1,843,500」
The 2021 stock options vested, with 421,500 shares exercised and 59,100 shares forfeited. The outstanding balance was 1,843,500 shares. - FY2024-Q3AdvancedAnnual report
「1 October 2023–31 December 2023 (Note) 78,300 287,436,942 23 25,350 23 6,584 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the third quarter, 78,300 shares were added through the exercise of stock acquisition rights, increasing share capital and capital surplus by ¥23 million each. - FY2023AdvancedAnnual report
「The increase in the total number of issued shares resulted from an increase of 191,572,428 shares due to a stock split and an increase of 333,300 shares from the issuance of new shares through the exercise of stock acquisition rights.」
The unvested balance of the 2021 stock options was 2,386,200 shares, while the issuance of 333,300 shares through the exercise of the 2017 stock options was confirmed. - FY2023-Q2AdvancedAnnual report
「1 July 2022–30 September 2022 (Note) 1 332,100 95,786,214 304 25,326 304 6,560 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
During the second quarter, 332,100 shares were added through the exercise of stock acquisition rights, increasing share capital and capital surplus by ¥304 million each. - FY2023-Q1AdvancedAnnual report
「1 April 2022–30 June 2022 (Note) 1,200 95,454,114 1 25,022 1 6,256 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the first quarter, 1,200 shares were added to issued shares through the exercise of stock acquisition rights, indicating the exercise of share-based compensation rights. - FY2022Partial forfeiture of 2021 stock optionsAnnual report
「Forfeited 6,500 Unvested balance 828,200」
Of the 2021 stock options, 6,500 shares were forfeited, leaving 828,200 shares unvested. - FY2022-Q3Expanded eligible recipients to directors and employeesAnnual report
「Resolution date 29 October 2021 Eligible persons and number Directors of the Company, excluding outside directors 8 Employees of the Company 1,230 Number of stock acquisition rights ※ 8,347 (Note) 1 Class, details and number of shares underlying the stock acquisition rights ※ Common shares 834,700 (Note) 1 Exercise period From 1 November 2023 to 31 October 2025」
Under the stock acquisition rights resolved on 29 October 2021, granted 8,347 rights covering 834,700 shares to 8 directors, excluding outside directors, and 1,230 employees. The eligible group was expanded from the previous grant to 5 directors. - FY2021AdvancedAnnual report
「Before vesting (shares) End of previous consolidated fiscal year 537,000 50,000 Vested 537,000 50,000 After vesting (shares) Exercised － － Forfeited 15,900 － Outstanding 521,100 50,000」
The 2017 and 2018 stock options vested during the year; 15,900 shares related to the 2017 stock options were forfeited, leaving 521,100 shares and 50,000 shares outstanding. - FY2019-Q2First statedAnnual report
「During the second quarter accounting period, the Company issued stock acquisition rights. Resolution date: 28 June 2018. Eligible persons and number: 5 directors of the Company, excluding outside directors. Number of stock acquisition rights: 500. Class, details and number of shares underlying the stock acquisition rights: common shares, 50,000 shares. Exercise period: from 14 September 2020 to 13 September 2022.」
Based on the resolution dated 28 June 2018, issued 500 stock acquisition rights covering 50,000 shares to 5 directors, excluding outside directors. The exercise period was set from 14 September 2020 to 13 September 2022.